In the United States, about 40 to 60 percent of all adults in the middle- and upper-socioeconomic classes show antibody proof of prior infection with CMV; antibody proof is as high as 80 percent in adults in the lower socioeconomic class.
Because antibody production does not usually begin in a previously unsensitized mother until after delivery, erythroblastosis in subsequent children can be prevented by giving the mother an injection of Rhogam within 72 hours of delivery.
If mononucleosis is suspected, a physician will typically conduct a physical examination, including a "Monospot" antibody blood test that can indicate the presence of proteins or antibodies produced in response to infection with the EBV.
As of 2004 no specific treatment cured common variable immunodeficiency; each child is treated according to the individual clinical condition, the symptoms presented, and the antibody subclasses shown to be absent or deficient.
Therefore, all mothers who have Rh-negative blood and no apparent sensitization (as indicated by antibody titer) should be treated with a standard 300g dose of Rh(D) immune globulin (Rhogam) at about 28 weeks of gestation.